DRG Market Assessment reports

Non-small-cell lung cancer (NSCLC) is the leading cause of cancer-related mortality in China. Treatment is based on biomarker status; patients with EGFR- and ALK-positive tumors generally receive…

Immune checkpoint inhibitors such as Opdivo (Bristol Myers Squibb / Ono Pharmaceutical) and Keytruda (Merck & Co.) have transformed gastroesophageal cancer treatment, driving significant market…

China accounts for nearly half of the cases of gastroesophageal cancer in the world, and its incidence there is expected to increase due to urbanization and an aging population. Current treatment…

Pancreatic cancer remains difficult to treat owing to the lack of treatment options—primarily surgery, radiation, and chemotherapy. Pancreatic adenocarcinoma represents the vast majority of…

The treatment landscape for small-cell lung cancer (SCLC) has seen significant advances in the past few years. Previously, chemotherapy and radiotherapy were the predominant treatments, but…

Clarivate Epidemiology’s coverage of liposarcoma comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany,…

The treatment landscape for endometrial carcinoma is rapidly evolving, driven by the growing adoption of immune checkpoint inhibitors and advancements in molecular classification. Although…

Clarivate Epidemiology’s coverage of soft tissue sarcoma (STS) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…

Clarivate Epidemiology’s coverage of soft tissue sarcoma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed incidence and…

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key soft tissue sarcoma patient populations, covering 171 countries and…

Clarivate Epidemiology’s coverage of thyroid cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed incidence and diagnosed…

Clarivate Epidemiology’s coverage of thyroid cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…